Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunic, Inc.

0.8049
-0.0390-4.62%
Post-market: 0.82000.0151+1.88%19:26 EDT
Volume:962.44K
Turnover:792.63K
Market Cap:77.12M
PE:-0.84
High:0.8600
Open:0.8300
Low:0.8005
Close:0.8439
Loading ...

Eqs-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients From Phase 2 Calliper Trial

THOMSON REUTERS
·
30 Apr

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

PR Newswire
·
30 Apr

One Immunic Insider Raised Their Stake In The Previous Year

Simply Wall St.
·
25 Apr

Immunic Price Target Maintained With a $6.00/Share by B. Riley Securities

Dow Jones
·
17 Apr

Immunic Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Apr

Immunic Raises $5.1 Million From Direct Stock Offering

MT Newswires Live
·
11 Apr

Eqs-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

THOMSON REUTERS
·
11 Apr

Immunic Announces $5.1 Million Securities Purchase Agreement

TIPRANKS
·
10 Apr

BRIEF-Immunic Announces Pricing Of $5.1 Million Registered Direct Offering

Reuters
·
09 Apr

Immunic Inc - Prices $5.1 Million Direct Offering at $0.90 per Share

THOMSON REUTERS
·
09 Apr

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

THOMSON REUTERS
·
09 Apr

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

PR Newswire
·
09 Apr

Immunic, US Steel, KLA, IIPR, Goodyear: Trending by Analysts

TIPRANKS
·
05 Apr

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
01 Apr

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

PR Newswire
·
01 Apr

Immunic Initiated at Outperform by William Blair

Dow Jones
·
25 Mar

William Blair Initiates Immunic at Outperform With $6.80 Price Target

MT Newswires Live
·
25 Mar

Buy Rating on Immunic Driven by Promising CALLIPER Study Outcomes and Market Opportunities in Progressive Multiple Sclerosis

TIPRANKS
·
25 Mar

Immunic’s Vidofludimus Calcium: A Promising Disruptor in the $45 Billion Multiple Sclerosis Market

TIPRANKS
·
25 Mar

Immunic to Participate in Scientific and Investor Conferences in March

PR Newswire
·
03 Mar